Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[surf1944]

7:49AM Tekmira Pharma announced a $65 mln settlement plus $10 mln in near-term milestone payments from Alnylam (ALNY) (TKMR) 5.12 : TKMR will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013. For the speculators who were betting on a positive outcome for the pending trial, the impact should be understandibly positive.

2:33AM Alnylam Pharma and Tekmira (TKMR) restructure relationship and settle all litigation (ALNY) 16.12 : Alnylam Pharmaceuticals (ALNY) announce that they and Tekmira Pharmaceuticals (TKMR) have restructured their relationship with a new licensing agreement and have resolved all litigation between the parties in a settlement agreement. The new license agreement consolidates and clarifies certain intellectual property elements related to lipid nanoparticle technology for RNAi therapeutics. Further, Alnylam has elected to independently manufacture its LNP-based RNAi therapeutic products and to buy-down certain future potential milestone payments and a significant portion of future potential royalties for its ALN-VSP, ALN-PCS, and ALN-TTR02 programs. The settlement of all ongoing litigation between the two companies allows Alnylam to continue to focus its efforts on advancing innovative medicines to patients. In addition, Alnylam has elected to buy out its manufacturing obligations to Tekmira with respect to its LNP-based pipeline programs. Alnylam will make a one-time payment of $30 million to Tekmira in order to have the rights to manufacture its own LNP-based products going forward. Further, Alnylam has elected to buy-down certain future potential milestone and royalty payments due to Tekmira for its ALN-VSP, ALN-PCS, and ALN-TTR02 LNP-based products. Specifically, Alnylam will make a one-time payment of $35 mln to Tekmira in association with the termination of the prior license agreements between the companies and the significant reduction in milestone and royalty payments for its ALN-VSP, ALN-PCS, and ALN-TTR02 products. Tekmira will also be eligible to receive an additional $10 mln in aggregate in contingent milestone payments related to advancement of ALN-VSP and ALN-TTR02 products, which now represent the only potential milestones for ALN-VSP, ALN-PCS and ALN-TTR02 products.